Spero Therapeutics to Collaborate with Central New York Research Corporation

Spero Therapeutics recently received a grant from the National Institue of Health (NIH) to conduct preclinical studies of SPR720, the company's novel oral bacterial gyrase inhibitor, for the treatment of tuberculosis (TB).

Spero will collaborate with the Central New York Research Corporation to asses the safety and efficacy of SPR720 in combination with rifampin and other existing standard-of-care drugs in preclinical models of both drug-susceptible TB and multidrug resistant (MDR) TB.  

Read the full release

Contact Us 

Central New York Research Corporation
800 Irving Avenue
Syracuse, New York 13210

P: (315) 425-4400 x53538
F: (315) 425-4871
E: info@cnyrc.org

Copyright © 2017 Central New York Research Corporation. All Rights Reserved.
Site Design: eKamria